Acute akathisia following initiation of opicapone: A case report.
作者信息
Baumgartner Alexander J, Adkins Michelle, Bainbridge Jacquelyn, Leehey Maureen A
机构信息
Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA.
Department of Clinical Pharmacy, University of Colorado School of Medicine, Aurora, CO, USA.
出版信息
Clin Park Relat Disord. 2022 Jul 19;7:100154. doi: 10.1016/j.prdoa.2022.100154. eCollection 2022.
Abstract
摘要
相似文献
1
Acute akathisia following initiation of opicapone: A case report.奥匹卡朋起始治疗后出现的急性静坐不能：一例报告。
Clin Park Relat Disord. 2022 Jul 19;7:100154. doi: 10.1016/j.prdoa.2022.100154. eCollection 2022.
2
Opicapone (Ongentys): A New COMT Inhibitor for the Treatment of Parkinson's Disease.奥匹卡朋（Ongentys）：一种用于治疗帕金森病的新型儿茶酚-O-甲基转移酶抑制剂。
Ann Pharmacother. 2021 Sep;55(9):1159-1166. doi: 10.1177/1060028020974560. Epub 2020 Nov 24.
3
Opicapone: A third generation COMT inhibitor.奥匹卡朋：一种第三代儿茶酚-O-甲基转移酶抑制剂。
Clin Park Relat Disord. 2020 Dec 7;4:100083. doi: 10.1016/j.prdoa.2020.100083. eCollection 2021.
4
Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.阿扑卡朋（第三代硝替卡朋）给药后食蟹猴脑及外周组织的左旋多巴药代动力学
Neuropharmacology. 2014 Feb;77:334-41. doi: 10.1016/j.neuropharm.2013.10.014. Epub 2013 Oct 19.
5
Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.在健康受试者中，新型儿茶酚-O-甲基转移酶抑制剂opicapone 的药代动力学、药效学和耐受性：对短半衰期和长作用时间抑制剂的缓慢酶-抑制剂复合物解离的预测。
Clin Pharmacokinet. 2013 Feb;52(2):139-51. doi: 10.1007/s40262-012-0024-7.
6
Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis.奥匹卡朋作为左旋多巴辅助治疗帕金森病患者运动波动的疗效和安全性：系统评价和荟萃分析。
J Parkinsons Dis. 2022;12(3):773-783. doi: 10.3233/JPD-213057.
7
Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration.在急性和重复给药后，opiocapone 抑制食蟹猴的儿茶酚-O-甲基转移酶。
Neuropharmacology. 2018 Dec;143:282-288. doi: 10.1016/j.neuropharm.2018.10.001. Epub 2018 Oct 2.
8
A single- and multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of opicapone, a novel COMT inhibitor, in rat.一项单次和多次剂量研究，旨在研究新型 COMT 抑制剂——opicapone 在大鼠中的药代动力学和药效学。
Neuropharmacology. 2017 Oct;125:146-155. doi: 10.1016/j.neuropharm.2017.07.019. Epub 2017 Jul 19.
9
Opicapone: Once-Daily COMT Inhibitor for the Treatment of Wearing Off in Parkinson's Disease.奥匹卡朋：每日一次的 COMT 抑制剂，用于治疗帕金森病的症状波动。
Sr Care Pharm. 2022 Feb 1;37(2):55-61. doi: 10.4140/TCP.n.2022.55.
10
Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.奥匹卡朋作为左旋多巴治疗帕金森病伴运动波动患者的辅助药物：一项随机临床试验。
JAMA Neurol. 2017 Feb 1;74(2):197-206. doi: 10.1001/jamaneurol.2016.4703.
本文引用的文献
1
Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges.重新审视抗精神病药物所致静坐不能：当前问题与未来挑战
Curr Neuropharmacol. 2017;15(5):789-798. doi: 10.2174/1570159X14666161208153644.
2
Akathisia, restless legs and periodic limb movements in sleep in Parkinson's disease.帕金森病中的静坐不能、不宁腿综合征和睡眠期周期性肢体运动。
Neurology. 2004 Oct 26;63(8 Suppl 3):S12-6. doi: 10.1212/wnl.63.8_suppl_3.s12.
3
Nonmotor fluctuations in Parkinson's disease: frequent and disabling.帕金森病的非运动波动：频繁且致残。
Neurology. 2002 Aug 13;59(3):408-13. doi: 10.1212/wnl.59.3.408.
4
[Akathisia secondary to tolcapone. Report of a case].[托卡朋所致静坐不能。1例报告]
Gac Med Mex. 2000 Sep-Oct;136(5):505-9.
5
Akathisia in Parkinson's disease.帕金森病中的静坐不能。
Mov Disord. 1994 Sep;9(5):545-9. doi: 10.1002/mds.870090507.
6
Akathisia in idiopathic Parkinson's disease.
Neurology. 1987 Mar;37(3):477-81. doi: 10.1212/wnl.37.3.477.
Zotero 插件